公开(公告)号：CA3082579A1

公开(公告)日：2019-05-23

申请号：CA3082579

申请日：2018-11-14

Applicant: MIRATI THERAPEUTICS INC ,  ARRAY BIOPHARMA INC

Inventor： BLAKE JAMES F ,  BURGESS LAURENCE E ,  CHICARELLI MARK JOSEPH ,  CHRISTENSEN JAMES GAIL ,  COOK ADAM ,  FELL JAY BRADFORD ,  FISCHER JOHN P ,  MARX MATTHEW ARNOLD ,  MEJIA MACEDONIO J ,  SAVECHENKOV PAVEL ,  VIGERS GUY P A ,  SMITH CHRISTOPHER RONALD ,  RODRIGUEZ MARTHA E

IPC: C07D401/06 ,  C07D401/14

Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：CA2771609C

公开(公告)日：2018-10-02

申请号：CA2771609

申请日：2010-08-18

Applicant: VENTIRX PHARMACEUTICALS INC ,  ARRAY BIOPHARMA INC

Inventor： HOWBERT JAMES JEFFRY ,  DIETSCH GREGORY ,  HERSHBERG ROBERT ,  BURGESS LAURENCE E ,  LYSSIKATOS JOSEPH P ,  NEWHOUSE BRAD ,  YANG HONG WOON

IPC: C07D223/16 ,  A61K31/55 ,  C07D405/02

Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.

公开(公告)号：HUE031797T2

公开(公告)日：2017-08-28

申请号：HUE10810564

申请日：2010-08-18

Applicant: VENTIRX PHARMACEUTICALS INC ,  ARRAY BIOPHARMA INC

Inventor： HOWBERT JAMES JEFFRY ,  DIETSCH GREGORY ,  HERSHBERG ROBERT ,  BURGESS LAURENCE E ,  DOHERTY GEORGE A ,  EARY C TODD ,  GRONEBERG ROBERT D ,  JONES ZACHARY

IPC: A61K31/55 ,  A61P31/00 ,  A61P35/00

公开(公告)号：AU2015357585A1

公开(公告)日：2017-07-13

申请号：AU2015357585

申请日：2015-12-04

Applicant: ARRAY BIOPHARMA INC ,  CELGENE CORP

Inventor： ALLEN SHELLEY ,  BOYS MARK LAURENCE ,  CHICARELLI MARK J ,  FELL JAY BRADFORD ,  FISCHER JOHN P ,  GAUDINO JOHN ,  HICKEN ERIK JAMES ,  HINKLIN RONALD JAY ,  KRASER CHRISTOPHER F ,  LAIRD ELLEN ,  ROBINSON JOHN E ,  TANG TONY P ,  BURGESS LAURENCE E ,  RIEGER ROBERT ANDREW ,  PHENEGER JED ,  SATOH YOSHITAKA ,  LEFTHERIS KATERINA ,  RAHEJA RAJ K ,  BENNETT BRYDON L

IPC: C07D487/04 ,  A61K31/4985 ,  A61P29/00 ,  A61P37/00

Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R

公开(公告)号：DK2467377T3

公开(公告)日：2017-04-03

申请号：DK10810563

申请日：2010-08-18

Applicant: VENTIRX PHARMACEUTICALS INC ,  ARRAY BIOPHARMA INC

Inventor： HOWBERT JAMES JEFFRY ,  DIETSCH GREGORY ,  HERSHBERG ROBERT ,  BURGESS LAURENCE E ,  LYSSIKATOS JOSEPH P ,  NEWHOUSE BRAD ,  YANG HONG WOON

IPC: C07D401/14 ,  A61K31/4025 ,  A61K31/454 ,  A61K31/55 ,  A61P31/00 ,  A61P35/00 ,  C07D223/14 ,  C07D403/10

公开(公告)号：BRPI0915513A2

公开(公告)日：2016-01-26

申请号：BRPI0915513

申请日：2009-06-24

Applicant: ARRAY BIOPHARMA INC

Inventor： COOK ADAM ,  CORRETTE CHRISTOPHER P ,  CLARK CHRISTOPHER T ,  KIM GANGHYEOK ,  DOHERTY GEORGE A ,  HUNT KEVIN W ,  BURGESS LAURENCE E ,  DELISLE ROBERT KIRK ,  ROMOFF TODD

IPC: C07D311/04 ,  A61K31/353 ,  A61P29/00 ,  C07D405/12 ,  C07D407/12

公开(公告)号：RS53665B1

公开(公告)日：2015-04-30

申请号：RSP20140627

申请日：2009-06-24

Applicant: ARRAY BIOPHARMA INC

Inventor： BURGESS LAURENCE E ,  CLARK CHRISTOPHER T ,  COOK ADAM ,  CORRETTE CHRISTOPHER P ,  DELISLE ROBERT KIRK ,  DOHERTY GEORGE A ,  HUNT KEVIN W ,  ROMOFF TODD ,  KIM GANGHYEOK

IPC: C07D311/04 ,  A61K31/353 ,  A61P29/00 ,  C07D405/12 ,  C07D407/12

Abstract: A compound which is 6-chloro-7-(4-(4-chloro-2-methoxyphenethylcarbamoyl)-phenoxy)chroman-4-carboxylic acid, or a pharmaceutically acceptable salt thereof. Said compound is either a racemic mixture or a single enantiomer, preferably Enantiomer 2 of 6-chloro-7-(4-(4-chloro-2-methoxyphenethylcarbamoyl)phenoxy)chroman-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, in particular its sodium salt. Said compound for use in treating an immunologic disorder in a mammal.

公开(公告)号：PH12014500079A1

公开(公告)日：2015-02-09

申请号：PH12014500079

申请日：2014-01-08

Applicant: ARRAY BIOPHARMA INC

Inventor： BURGESS LAURENCE E ,  CLARK CHRISTOPHER T ,  ADAM COOK ,  CORRETTE CHRISTOPHER P ,  KIRK DELISLE ROBERT ,  DOHERTY GEORGE A ,  HUNT KEVIN W ,  TODD ROMOFF ,  GANGHYEOK KIM

IPC: A61P29/00 ,  A61K31/353 ,  C07D311/04 ,  C07D405/12 ,  C07D407/12

Abstract: Compounds of Formula (I): in which A1, A2, W, L, G, R7a, R7b, R8, R9 and R10 have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.

公开(公告)号：SG2014013544A

公开(公告)日：2014-07-30

申请号：SG2014013544

申请日：2009-06-24

Applicant: ARRAY BIOPHARMA INC

Inventor： CLARK CHRISTOPHER T ,  COOK ADAM ,  CORRETTE CHRISTOPHER P ,  DELISLE ROBERT KIRK ,  DOHERTY GEORGE A ,  HUNT KEVIN W ,  ROMOFF TODD ,  GANGHYEOK KIM ,  BURGESS LAURENCE E

Abstract: A compound which is 6-chloro-7-(4-(4-chloro-2-methoxyphenethylcarbamoyl)-phenoxy)chroman-4-carboxylic acid, or a pharmaceutically acceptable salt thereof. Said compound is either a racemic mixture or a single enantiomer, preferably Enantiomer 2 of 6-chloro-7-(4-(4-chloro-2-methoxyphenethylcarbamoyl)phenoxy)chroman-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, in particular its sodium salt. Said compound for use in treating an immunologic disorder in a mammal.

公开(公告)号：NZ603446A

公开(公告)日：2014-05-30

申请号：NZ60344611

申请日：2011-04-11

Applicant: ARRAY BIOPHARMA INC

Inventor： BOYS MARK LAURENCE ,  BURGESS LAURENCE E ,  GRONEBERG ROBERT D ,  HARVEY DARREN M ,  HUANG LILY ,  KERCHER TIMOTHY ,  KRASER CHRISTOPHER F ,  LAIRD ELLEN ,  TARLTON EUGENE ,  ZHAO QIAN

IPC: C07D487/04 ,  A61K31/519 ,  A61P29/00 ,  A61P37/00

Abstract: Disclosed are 5,7-substituted-imidazo[1,2-C]pyrimidine’s as inhibitors of JAK kinases of formula (I). The compounds are useful in the treatment of autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their comorbidities. Examples of compounds of formula (I) are: 2-(3-(3-(7-(1-Methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile hydrochloride; 3-Cyclopropyl-3-(3-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile; and 3-cyclopentyl-3-(4-(7-(4-(1-methylpiperidin-4-yl)phenyl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and the use of a compound of formula (I) in the manufacture of a medicament for the treatment of an autoimmune disease or inflammatory disease; organ, tissue or cell transplant rejection; or malignancy.